TWO · Healthcare

Taiwan Bio Therapeutics Co., Ltd (6892)

Biotechnology

Taiwan Bio Therapeutics Co., Ltd (6892) is listed on TWO in the Healthcare sector. Industry: Biotechnology. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for 6892

P/E ratio

18.00

Taiwan Bio Therapeutics Co., Ltd (6892) — FAQ

What is 6892's P/E ratio?

The price-to-earnings (P/E) ratio for Taiwan Bio Therapeutics Co., Ltd (6892) is 18.00 (data as of 2026-03-23).

Does Taiwan Bio Therapeutics Co., Ltd pay a dividend?

Dividend yield is not available in the current snapshot for Taiwan Bio Therapeutics Co., Ltd (6892). Check the MyAverix Finance app for the latest dividend data.

What sector is Taiwan Bio Therapeutics Co., Ltd in?

Taiwan Bio Therapeutics Co., Ltd (6892) is classified in the Healthcare sector (Biotechnology industry).

What exchange is 6892 listed on?

6892 is listed on TWO.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)